University of Michigan Medical School-ko ikertzaileekin lankidetzan egindako argitalpenak (26)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  4. Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma

    Nature Communications, Vol. 15, Núm. 1

  5. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

    Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525

2023

  1. Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

    Blood, Vol. 141, Núm. 9, pp. 1047-1059

  2. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  3. Regulation and role of the PP2A-B56 holoenzyme family in cancer

    Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1878, Núm. 5

  4. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2022

  1. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  2. Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential

    British Journal of Cancer, Vol. 126, Núm. 11, pp. 1595-1603

  3. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

    Nature Medicine, Vol. 28, Núm. 3, pp. 557-567

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Hematopoiesis under telomere attrition at the single-cell resolution

    Nature Communications, Vol. 12, Núm. 1

2017

  1. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502

2016

  1. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis

    Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2468-2477

2015

  1. Characterization of large structural genetic mosaicism in human autosomes

    American Journal of Human Genetics, Vol. 96, Núm. 3, pp. 487-497

  2. Consensus nomenclature for CD8+ T cell phenotypes in cancer

    OncoImmunology, Vol. 4, Núm. 4

2014

  1. Consensus guidelines for the detection of immunogenic cell death

    OncoImmunology, Vol. 3, Núm. 9

  2. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma

    Cancer Cell, Vol. 25, Núm. 6, pp. 735-747